Phaseline

Companies › CellTrans

CellTrans: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 2 Phase 3, 1 Phase 2, 1 Phase 1; Genitourinary, Metabolic and endocrine, Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Basiliximab
Interleukin-2 receptor inhibitor
IL2RA, IL2RG, IL2RBPhase 3Type 1 Diabetes Mellitus; Renal Transplant Rejection; Recurrent Hodgkin Lymphoma; Acute Lymphoblastic Leukemia–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT00679042BasiliximabPhase 3Type 1 Diabetes MellitusMetabolic and endocrineJul 2017
NCT05139004BasiliximabPhase 1Acute Lymphoblastic LeukemiaOncologyJun 2027
NCT04871607BasiliximabPhase 2Recurrent Hodgkin LymphomaOncologyOct 2029
NCT05385432BasiliximabPhase 3Renal Transplant RejectionGenitourinaryDec 2030

From the company's SEC filings

Complete response letters from FDA

Targets

IL2RA (1) IL2RG (1) IL2RB (1)

Companies with the same targets

AgonOx Sanofi ImmunityBio Nektar Therapeutics Regeneron Pharmaceuticals Mural Oncology PolTREG GI Innovation Synthekine

Companies built like this

HealthTech Wound Care PolarityTE Royal Biologics Innovacell Ascendis Pharma Bone Diseases

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.